[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @_Sgr_A_Star The God Particle The God Particle posts on X about hims, $hims, bearish, $abbv the most. They currently have XXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::2508560796/interactions)  - X Week XXXXX +64% - X Month XXXXXX -XX% - X Months XXXXXXX +535% - X Year XXXXXXX +20,193% ### Mentions: XX [#](/creator/twitter::2508560796/posts_active)  - X Months XXX +176% - X Year XXX +6,675% ### Followers: XXX [#](/creator/twitter::2508560796/followers)  - X Week XXX +11% - X Month XXX +30% - X Months XXX +2,333% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::2508560796/influencer_rank)  ### Social Influence [#](/creator/twitter::2508560796/influence) --- **Social category influence** [stocks](/list/stocks) [finance](/list/finance) [automotive brands](/list/automotive-brands) **Social topic influence** [hims](/topic/hims) #78, [$hims](/topic/$hims), [bearish](/topic/bearish), [$abbv](/topic/$abbv), [gilead sciences](/topic/gilead-sciences), [investment](/topic/investment), [10k](/topic/10k) **Top assets mentioned** [Hims & Hers Health, Inc. (HIMS)](/topic/$hims) [AbbVie Inc (ABBV)](/topic/$abbv) [Gilead Sciences, Inc. (GILD)](/topic/gilead-sciences) ### Top Social Posts [#](/creator/twitter::2508560796/posts) --- Top posts by engagements in the last XX hours "@YeezyMoney123 Assuming Q2 ends up at 560M (my estimate) it would require 1.2-1.3B to reach the 2.3-2.4B FY XX guidance. If Q3 comes in at 600M then meeting exceeding FY2025 guidance is almost a certainty as Q4 typically sees the biggest sequential incremental revenue (intra-year)"  [@_Sgr_A_Star](/creator/x/_Sgr_A_Star) on [X](/post/tweet/1949001982418845973) 2025-07-26 07:00:57 UTC XXX followers, XXX engagements "How fucking dare $HIMS adjust their prices due to changing consumer behaviors dynamic competitive landscape supply and demand dynamics ever changing costs and new strategic objectives. Who the fuck do they think they are a for-profit (insert facepalm emoji) At this point Paul even Spruce Point s'gotta think you're making shorts look bad"  [@_Sgr_A_Star](/creator/x/_Sgr_A_Star) on [X](/post/tweet/1948474507221741895) 2025-07-24 20:04:58 UTC XXX followers, XXX engagements "I'm not sure how I feel about these news: On the one hand. Unless $HIMS decides to start selling compounded Tirzepatide as well (which they've said in the past they wouldn't) these news introduce a better drug at competitive prices into the compounded/personalized GLP1 space. Bearish. On the other hand. If compounded Tirzepatide is back in production (for legitimate reasons) it provides HIMS' more "legal cover" and once again (temporarily) de-risks their personalized sema sales. Bullish"  [@_Sgr_A_Star](/creator/x/_Sgr_A_Star) on [X](/post/tweet/1949156422090211611) 2025-07-26 17:14:39 UTC XXX followers, XXX engagements "@himshouse HIMS helping TSLA cross the FSD finish line š¤Æ"  [@_Sgr_A_Star](/creator/x/_Sgr_A_Star) on [X](/post/tweet/1948577447236305263) 2025-07-25 02:54:00 UTC XXX followers, XXX engagements "All you need to know Pere: Donors At the Center for Medicine in the Public Interest we acknowledge the generosity of our donors and their dedication to our mission and the advancement of healthcare policy. AbbVie Inc. Amicus Therapeutics APCO Worldwide Aprecia Pharmaceuticals BIO Bristol Myers Squibb ChromaDex Ewing Marion Kauffman Foundation Gilead Sciences Inc. GSK Juul Labs The Lilly Foundationš¤” Merck & Co. National Community Pharmacists Association Novo Nordisk Inc. š¤” Pfizer Inc. PhRMA Sarepta Therapeutics Searle Freedom Trust Stand Together Trust Standup4Nurses"  [@_Sgr_A_Star](/creator/x/_Sgr_A_Star) on [X](/post/tweet/1949292445726065023) 2025-07-27 02:15:09 UTC XXX followers, XXX engagements "Your 2030E revenue estimate is XX% lower than $HIMS 6.5B sandbag guidance for 2030. I get trying to be conservative in one's estimates to build in a margin of safety but I think you're a little too conservative. Here is my "conservative" DCF going out XX years and my current fair value"  [@_Sgr_A_Star](/creator/x/_Sgr_A_Star) on [X](/post/tweet/1948388210931057046) 2025-07-24 14:22:03 UTC XXX followers, XXX engagements "@nikoliasgoninus @DueDoctor While I'm at it. The revenue growth contributions based on 2025 guidance will be 875M (2.35B - 1.48B). By my math GLP1 revenue will grow by 600M over 2024 this year. (825M vs 225M). How is HIMS not a GLP1 company right now Nikolas"  [@_Sgr_A_Star](/creator/x/_Sgr_A_Star) on [X](/post/tweet/1934446789312352373) 2025-06-16 03:03:49 UTC XXX followers, XX engagements "It's still early because analysts are likely to update their estimates after Q2 earnings but. As of now the mean consensus estimate for Q3 revenue growth Y/Y is XXXX% which translates to 593M revenue estimate for Q3. On track. One last point - by the first X weeks of a quarter it's pretty clear what the quarterly projection is going to be and it doesn't deviate much from the projection"  [@_Sgr_A_Star](/creator/x/_Sgr_A_Star) on [X](/post/tweet/1949152367771078869) 2025-07-26 16:58:32 UTC XXX followers, XXX engagements "It's your largest investment. You don't know your investment like you think you do homie. Me selling you on @himshouse was mostly sarcasm but the part that wasn't really does think you'd benefit greatly from being a Hims Homie. A more informed investor makes more informed decisions. A more informed investor base leads to more diamond hands. Get informed"  [@_Sgr_A_Star](/creator/x/_Sgr_A_Star) on [X](/post/tweet/1949538402027872261) 2025-07-27 18:32:30 UTC XXX followers, XX engagements "@ElijahCablerF @himshouse This isn't predicting earnings. This is guessing earnings. Stop guessing start actually predicting. Become a Hims Homie. Quants like @NighthawkTradez share real data that will make you Nostradamus by next earnings"  [@_Sgr_A_Star](/creator/x/_Sgr_A_Star) on [X](/post/tweet/1949539934567854361) 2025-07-27 18:38:35 UTC XXX followers, XXX engagements "There is no huge shift. the company had already made it abundantly clear even put it in their 10K that a "significant majority" (their words) of GLP-1 subscribers were/are already on personalized dosages. By my math XX% represents "significant majority". The other XX% (commercial) were either converted to Oral/Liraglutide/Retail Price (probably a very small %) with the rest being rolled off the platform (probably most). It's the members being rolled off the platform (most) that put pressure on New New Subscribers in Q1 and Q2"  [@_Sgr_A_Star](/creator/x/_Sgr_A_Star) on [X](/post/tweet/1949537231250886767) 2025-07-27 18:27:51 UTC XXX followers, XX engagements "No it would be fantastic. That's $HIMS' DNA. Source generics at extremely cheap prices attach a primary care physician and platform to them and sell them for 5x the cost of the generics (that's how you get to XX% gross margins). Buy generic for $X attach a doctor/platform sell it for $X make $X in gross profits (80%)"  [@_Sgr_A_Star](/creator/x/_Sgr_A_Star) on [X](/post/tweet/1948426242040238567) 2025-07-24 16:53:10 UTC XXX followers, XXX engagements "@himshouse @ElijahCablerF @NighthawkTradez I'm trying to get you more Hims Homies J I'd give you my referralink but you're already a member Let's get these retail shares in informed diamond hands instead of these uninformed paper hands. Shine bright like a diamond Elijah. Get informed"  [@_Sgr_A_Star](/creator/x/_Sgr_A_Star) on [X](/post/tweet/1949575598554386714) 2025-07-27 21:00:18 UTC XXX followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@_Sgr_A_Star The God Particle
The God Particle posts on X about hims, $hims, bearish, $abbv the most. They currently have XXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXX +64%
- X Month XXXXXX -XX%
- X Months XXXXXXX +535%
- X Year XXXXXXX +20,193%
Mentions: XX #
- X Months XXX +176%
- X Year XXX +6,675%
Followers: XXX #
- X Week XXX +11%
- X Month XXX +30%
- X Months XXX +2,333%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence stocks finance automotive brands
Social topic influence hims #78, $hims, bearish, $abbv, gilead sciences, investment, 10k
Top assets mentioned Hims & Hers Health, Inc. (HIMS) AbbVie Inc (ABBV) Gilead Sciences, Inc. (GILD)
Top Social Posts #
Top posts by engagements in the last XX hours
"@YeezyMoney123 Assuming Q2 ends up at 560M (my estimate) it would require 1.2-1.3B to reach the 2.3-2.4B FY XX guidance. If Q3 comes in at 600M then meeting exceeding FY2025 guidance is almost a certainty as Q4 typically sees the biggest sequential incremental revenue (intra-year)"
@_Sgr_A_Star on X 2025-07-26 07:00:57 UTC XXX followers, XXX engagements
"How fucking dare $HIMS adjust their prices due to changing consumer behaviors dynamic competitive landscape supply and demand dynamics ever changing costs and new strategic objectives. Who the fuck do they think they are a for-profit (insert facepalm emoji) At this point Paul even Spruce Point s'gotta think you're making shorts look bad" @_Sgr_A_Star on X 2025-07-24 20:04:58 UTC XXX followers, XXX engagements
"I'm not sure how I feel about these news: On the one hand. Unless $HIMS decides to start selling compounded Tirzepatide as well (which they've said in the past they wouldn't) these news introduce a better drug at competitive prices into the compounded/personalized GLP1 space. Bearish. On the other hand. If compounded Tirzepatide is back in production (for legitimate reasons) it provides HIMS' more "legal cover" and once again (temporarily) de-risks their personalized sema sales. Bullish" @_Sgr_A_Star on X 2025-07-26 17:14:39 UTC XXX followers, XXX engagements
"@himshouse HIMS helping TSLA cross the FSD finish line š¤Æ" @_Sgr_A_Star on X 2025-07-25 02:54:00 UTC XXX followers, XXX engagements
"All you need to know Pere: Donors At the Center for Medicine in the Public Interest we acknowledge the generosity of our donors and their dedication to our mission and the advancement of healthcare policy. AbbVie Inc. Amicus Therapeutics APCO Worldwide Aprecia Pharmaceuticals BIO Bristol Myers Squibb ChromaDex Ewing Marion Kauffman Foundation Gilead Sciences Inc. GSK Juul Labs The Lilly Foundationš¤” Merck & Co. National Community Pharmacists Association Novo Nordisk Inc. š¤” Pfizer Inc. PhRMA Sarepta Therapeutics Searle Freedom Trust Stand Together Trust Standup4Nurses" @_Sgr_A_Star on X 2025-07-27 02:15:09 UTC XXX followers, XXX engagements
"Your 2030E revenue estimate is XX% lower than $HIMS 6.5B sandbag guidance for 2030. I get trying to be conservative in one's estimates to build in a margin of safety but I think you're a little too conservative. Here is my "conservative" DCF going out XX years and my current fair value" @_Sgr_A_Star on X 2025-07-24 14:22:03 UTC XXX followers, XXX engagements
"@nikoliasgoninus @DueDoctor While I'm at it. The revenue growth contributions based on 2025 guidance will be 875M (2.35B - 1.48B). By my math GLP1 revenue will grow by 600M over 2024 this year. (825M vs 225M). How is HIMS not a GLP1 company right now Nikolas" @_Sgr_A_Star on X 2025-06-16 03:03:49 UTC XXX followers, XX engagements
"It's still early because analysts are likely to update their estimates after Q2 earnings but. As of now the mean consensus estimate for Q3 revenue growth Y/Y is XXXX% which translates to 593M revenue estimate for Q3. On track. One last point - by the first X weeks of a quarter it's pretty clear what the quarterly projection is going to be and it doesn't deviate much from the projection" @_Sgr_A_Star on X 2025-07-26 16:58:32 UTC XXX followers, XXX engagements
"It's your largest investment. You don't know your investment like you think you do homie. Me selling you on @himshouse was mostly sarcasm but the part that wasn't really does think you'd benefit greatly from being a Hims Homie. A more informed investor makes more informed decisions. A more informed investor base leads to more diamond hands. Get informed" @_Sgr_A_Star on X 2025-07-27 18:32:30 UTC XXX followers, XX engagements
"@ElijahCablerF @himshouse This isn't predicting earnings. This is guessing earnings. Stop guessing start actually predicting. Become a Hims Homie. Quants like @NighthawkTradez share real data that will make you Nostradamus by next earnings" @_Sgr_A_Star on X 2025-07-27 18:38:35 UTC XXX followers, XXX engagements
"There is no huge shift. the company had already made it abundantly clear even put it in their 10K that a "significant majority" (their words) of GLP-1 subscribers were/are already on personalized dosages. By my math XX% represents "significant majority". The other XX% (commercial) were either converted to Oral/Liraglutide/Retail Price (probably a very small %) with the rest being rolled off the platform (probably most). It's the members being rolled off the platform (most) that put pressure on New New Subscribers in Q1 and Q2" @_Sgr_A_Star on X 2025-07-27 18:27:51 UTC XXX followers, XX engagements
"No it would be fantastic. That's $HIMS' DNA. Source generics at extremely cheap prices attach a primary care physician and platform to them and sell them for 5x the cost of the generics (that's how you get to XX% gross margins). Buy generic for $X attach a doctor/platform sell it for $X make $X in gross profits (80%)" @_Sgr_A_Star on X 2025-07-24 16:53:10 UTC XXX followers, XXX engagements
"@himshouse @ElijahCablerF @NighthawkTradez I'm trying to get you more Hims Homies J I'd give you my referralink but you're already a member Let's get these retail shares in informed diamond hands instead of these uninformed paper hands. Shine bright like a diamond Elijah. Get informed" @_Sgr_A_Star on X 2025-07-27 21:00:18 UTC XXX followers, XXX engagements